Collegium Pharmaceutical (COLL) Short-term Investments (2014 - 2026)

Collegium Pharmaceutical has reported Short-term Investments for 5 years, with the latest figure at $19.8 million in Q2 2026.

• On a quarterly basis, Short-term Investments fell 81.06% year-over-year to $19.8 million in Q2 2026; TTM through Jun 2026 was $19.8 million, a 81.06% decrease from a year earlier, with the FY2025 full-year figure at $155.4 million, up 68.58% from the prior year.
• Short-term Investments was $19.8 million for Q2 2026 at Collegium Pharmaceutical, down from $153.1 million in the prior quarter.
• The five-year high for Short-term Investments was $155.4 million in Q4 2025, with the low at $19.8 million in Q2 2026.
• Average Short-term Investments over 4 years is $91.6 million, with a median of $92.2 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2026: Short-term Investments surged 136.66% in 2024, then sank 81.06% in 2026.
• Over 4 years, Short-term Investments stood at $71.6 million in 2023, then climbed by 28.77% to $92.2 million in 2024, then surged by 68.58% to $155.4 million in 2025, then tumbled by 87.23% to $19.8 million in 2026.
• The last three Short-term Investments figures came in at $19.8 million (Q2 2026), $153.1 million (Q1 2026), and $155.4 million (Q4 2025), per Business Quant data.